Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Fig. 4

a. 5-year disease-free survival (DFS) in patients with TIM3 (≥1%), 50.5%, vs TIM3 (< 1%), 65.6%; p = 0.473. b. 5-year disease-specific survival (DSS) in patients with TIM3 (≥1%), 53.6%, vs TIM3 (< 1%), 72.3%; p = 0.524. c. 5-year disease-free survival (DFS) in patients with LAG3 (≥1%), 68.8% vs LAG3 (< 1%), 50.8%; p = 0.37. d. 5-year disease-specific survival (DSS) in patients with LAG3 (≥1%), 60.6%, vs LAG3 (< 1%), 59.4%; p = 0.778

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us